CORRECTING and REPLACING Pharmacyclics/Janssen Biotech's PCI-32765 Has Earned ... Business Wire (press release) Rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo's Rituxan/MabThera) will continue to dominate a more fragmented diffuse large B-cell lymphoma market over the forecast period, despite the entry of less-expensive biosimilar versions of rituximab. |
